97.32 0.00 (0.00%)
After hours: 4:25PM EDT
|Bid||97.36 x 1100|
|Ask||97.37 x 1200|
|Day's Range||97.05 - 97.74|
|52 Week Range||81.66 - 100.15|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||28.54|
|Earnings Date||Aug 20, 2019|
|Forward Dividend & Yield||2.00 (2.16%)|
|1y Target Est||103.17|
All eyes are on the US Federal Reserve right now. On Wednesday, the Fed will reveal whether it decides to slash interest rates or keep them steady at 2.25% - 2.50%. Ahead of the announcement, the general consensus is that the Fed will keep rates steady but set the groundwork for cuts when it next meets in July. “The markets are set up for a cut in July, and if they don’t get it, financial conditions will tighten” Carl Tannenbaum, chief economist at Northern Trust, told Reuters.So how should investors prepare their portfolios going forward? Goldman Sachs has some advice. “If the Fed does cut rates, the S&P 500 usually rallies afterward, with health care and consumer staples outperforming and information technology consistently lagging,” Goldman's chief U.S. equity strategist David Kostin said. The “communication services sector has generated the best relative returns and hit rate of outperformance during the subsequent 3 months (+4 pp, 100%), but has underperformed over a 12-month horizon.”Here we take a closer look at three stocks that fit into these two categories, with 2 healthcare stocks and 1 consumer staples stock. What’s more, all three of these stocks show a ‘Strong Buy’ Street consensus. That’s based on all ratings received over the last three months. Let’s take a closer look at why analysts are so bullish on these stocks now: 1\. Boston Scientific (BSX)Boston Scientific manufactures medical devices used in interventional medical specialties, including everything from needles to pacemakers. Shares are up 14% year-to-date, and over 80% on a three-year basis. Right now, the company is gearing up for its investor day on June 26. This is the first event since 2017- and expectations are high that BSX met or exceeded all of the 2017 and 2018 financial targets. Needham analyst Mike Matson is confident that BSX can sustain high single digit growth over the next few years, and expects it to target organic revenue growth of 7-9% from 2019 to 2022 at the event. “Given BSX’s strong fundamentals (durable high single digit revenue growth, diversified product portfolio, margin expansion potential, etc.), we believe there is potential for upside to consensus estimates and additional multiple expansion and we reiterate our Strong Buy rating” writes Matson. He reiterated his BSX ‘Buy’ rating on June 14 with a $46 price target (14% upside potential). As we can see here the stock has received 9 recent buy ratings and 1 hold rating:View BSX Price Target & Analyst Ratings Detail 2\. Medtronic (MDT)Ireland-based Medtronic is one of the world’s largest medical device makers. Although the company manufactures a wide range of products, most of the hype right now is centered on the MazorX robotic platform. Medtronic snapped up Mazor Robotics for $1.7 billion late last year, and the two companies have now developed the MazorX Stealth Edition robotic guidance platform. The power of the platform is a preoperative planning suite with 3D analytics and tools, which allows surgeons to optimize the surgical process in advance. “Part of MDT’s revenue acceleration thesis depends on the success of MazorX in driving spine share gains” writes Evercore ISI analyst Vijay Kumar. He recently reiterated his Medtronic Buy rating with a $108 price target. “We think MDT’s view of ‘several hundred bps of share gains’ in spine remains a credible thesis given early trends we are seeing. Extrapolating these to general surgery (~80% systems placed for committed implant / consumable volume) lends further credence to why we think robotic surgery could be a big deal for MDT” writes Kumar. The analyst concludes: “We think MDT is the perfect stock for a choppy environment, and should be a core holding given this revenue reacceleration thesis.” That’s alongside Wells Fargo analyst Larry Biegelsen upgrading Medtronic from Hold to Buy with a $110 price target. The analyst comments "We believe MDT is an accelerating growth story trading at a steep discount to its peers."Overall 7 analysts have published buy ratings on MDT in the last three months, with just 2 analysts staying sidelined.View MDT Price Target & Analyst Ratings Detail 3\. Tyson Foods (TSN)While many investors are pouring money into Beyond Foods, it’s also worth taking a closer look at Tyson Foods. This is the world's second largest processor and marketer of chicken, beef, and pork. However the company has also recently branched out into plant-based meat alternatives, including chicken nuggets and patties. Shares have rocketed with a 53% gain so far year-to-date. Boosting prices further was a rating upgrade from Argus Research’s John Staszak. He has a $92 price target on TSN (12% upside potential).Staszak cited a “growing demand for proteins" and notes that Tyson's beef division is experiencing "especially strong demand". Plus the company is working hard to increase prepared foods sales to satisfy the "steady demand and strong margins." And to top of it, Tyson trades at a multiple of just 12.8-times forward earnings, which is below the average large-cap food processor multiple of 18.4-times. It’s also easily towards the low end of Tyson’s own historical 9- to 19-times range. The stock boasts 7 recent bullish calls, with only 1 analyst publishing a Sell rating (Pivotal Research's Timothy Ramey). View TSN Price Target & Analyst Ratings Detail Discover stock ideas from the Street’s best performing analysts here
A nonsurgical method of heart-valve replacement, dubbed TAVR, is gaining steam in the U.S. — propping up medical technology companies Edwards and Medtronic, an analyst said Friday.
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer spoke with Kevin Sayer, chairman, president and CEO of Dexcom Inc. The trend-following Moving Average Convergence Divergence (MACD) oscillator just moved above the zero line for an outright buy signal on this time frame.
Logistics firm DHL Supply Chain will expand its medical device and pharmaceutical logistics business in Memphis, bringing about 50 more jobs and $8 million in capital investment.
Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.
Medtronic PLC NYSE:MDTView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MDT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MDT. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MDT had net inflows of $5.04 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
June 10, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world data on its Guardian(TM) Connect continuous glucose monitoring (CGM) system and Sugar.IQ(TM) diabetes assistant app presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) Annual Meeting in San Francisco. The data presented were recorded by users of the Guardian Connect system paired with Sugar.IQ diabetes assistant, a separate first-of-its-kind intelligent app that continually analyzes how an individual`s glucose levels respond to food intake, insulin dosages, daily routines and other factors1. The Sugar.IQ app combines data from the Guardian Connect system with artificial intelligence technology from Medtronic`s strategic partner, IBM® Watson Health, to detect important patterns and trends for people with diabetes and help them make more informed decisions on how to better manage glucose levels and stay within target range.
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
Tandem Diabetes stock skidded Monday as investors questioned whether the medical devices maker could catch up to industry leader Medtronic in diabetes treatment using a pump and monitor.
Four Year Partnership Made Public Today DUBLIN - June 10, 2019 - To enable upcoming regulatory filings, Medtronic plc (NYSE:MDT) today made public its partnership with KARL STORZ SE & Co. KG (Tuttlingen, ...
June 8, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced the enrollment of the first study participants in the company`s pivotal trial of its Bluetooth® enabled MiniMed(TM) 780G advanced hybrid closed loop (AHCL) system. This next-generation system is designed to automate the delivery of correction boluses when the user experiences, or is predicted to experience, prolonged high glucose levels based on their sensor readings. The trial will evaluate the safety of the MiniMed 780G system in participants with type 1 diabetes at home, at work, during exercise and other daily activities.
June 8, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it has initiated the company`s pivotal trial for its next-generation Guardian(TM) continuous glucose monitoring (CGM) sensor designed to improve accuracy and overall system performance, reduce sensor calibrations and enhance overall user experience. The multi-center, prospective trial will study the next-generation CGM sensor in up to 460 participants with type 1 or type 2 diabetes aged two to 80 years old over the course of seven days. Study participants will be randomly assigned to sensor wear location and testing days and times.
June 7, 2019 - Medtronic plc (MDT), the global leader in medical technology, services and solutions, and Tidepool, a 501(c)(3) nonprofit organization dedicated to making diabetes data more accessible, actionable and meaningful, have agreed to work together to create an interoperable automated insulin pump system. Medtronic will develop a future Bluetooth-enabled MiniMed(TM) pump that would be compatible with Tidepool Loop, a future FDA-regulated, open source automated insulin delivery app for iPhone® and Apple Watch® currently in development. "We think that Medtronic is making a very bold and important move here that shows tremendous courage and is the absolutely right thing for the diabetes community," said Howard Look, founder and CEO of Tidepool.
Sometimes CEO's deserve the benefit the of the doubt, Jim Cramer reminded viewers on Mad Money. In this daily bar chart of MDT, below, we can see a number of bullish developments. The daily On-Balance-Volume (OBV) line has been in an uptrend the past 12 months and recently made a new high for the move up.
Medtronic PLC (NYSE: MDT ) has earned a bullish review from Wells Fargo Securities, which premised its optimistic outlook on the company's growth prospects. The Analyst Larry Biegelsen upgraded Medtronic ...
The largest Insider Buys this week were for Medtronic PLC (MDT), General Electric Co. (GE), Keurig Dr Pepper Inc. (KDP) and Phillips 66 (PSX). Director Richard H. Anderson bought 10,900 shares of MDT stock on May 24 at the average price of $92.4. Warning! GuruFocus has detected 5 Warning Signs with MDT.
Medical technology companies Intuitive Surgical and Medtronic could feel the pressure as President Donald Trump ratchets up tariffs on Mexican imports, beginning June 10, an analyst says.
May 29, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, California. Omar Ishrak, Medtronic chairman and chief executive officer, will answer questions about the company beginning at 11:20 a.m. PDT (1:20 p.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
May 29, 2019 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) clearance and commercial launch for the SelectSite(TM) C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing (HBP). The SelectSite C304-HIS deflectable catheter system features a deflectable, out-of-plane curve to reach the bundle of His and is designed to enable enhanced range maneuverability, fixation and implant success for a wider range of patient anatomies. The new catheter system facilitates placement of the Medtronic SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead, the only pacing lead on the U.S. market approved for HBP.
An introduction to health care companies that are tops in their fields. From health care provider to pharmaceuticals, these companies have the largest global presence according to market capitalization. Learn who these health care giants are and why they may be a good investment.
Is Medtronic an Attractive Pick after Its Q4 Results?(Continued from Prior Part)Revenue growth guidanceOn its fourth-quarter earnings conference call, Medtronic (MDT) guided for YoY (year-over-year) organic revenue growth of 4.5%–5% for its
Phil Davidson, a longtime co-manager of the American Century Equity Income Fund, notes that the highest-yielding stocks haven’t performed all that well in recent years.